ADL Amdl,

TUSTIN, Calif., Dec. 15 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that Mercy Bio Technology Co., Ltd., has received Department of Health approval to market DR-70(R), AMDL's non-invasive cancer blood test kit, in Taiwan. Cancer is the leading cause of death in Taiwan, with one of every four deaths attributable to this disease. The smoking rate in Taiwan is high and pollution from industry is significant. The Taiwanese government has launched major cancer control programs to prevent or control the more common cancers and has instituted large community cancer-screening programs. "There is an enormous awareness of cancer in Taiwan and major efforts are underway to combat this disease. DR-70(R) can play a huge role in this effort. We believe that we have chosen an excellent distributor with qualified marketing and technical expertise for this important task," said Gary Dreher, AMDL President & CEO. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 14 cancers 84 percent of the time overall. Clinical trials of DR-70(R) have been conducted in China, Canada, Taiwan and Turkey. Cancers that can be detected are colon, breast, stomach, liver, rectal, ovarian, cervical, esophageal, thyroid, pancreatic, trophoblastic and malignant lymphoma. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdlcorporate.com/. Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdlcorporate.com/

Copyright